New AIDS Clinical Trials Unit Study Opens

ACTG Study 5142

A study to compare the effectiveness of three regimens for the initial treatment of HIV Infection

The study will examine the use of a lopinavir/ritonavir (a ritonavir-enhanced, second generation protease inhibitor)-based regimen, a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, and a nucleoside-sparing regimen as the first treatment of HIV-1 infection.

Eligibility:

• HIV positive
  Advertisement
• Planning to start anti-HIV treatment

• No prior antiretroviral therapy

• 18 years old or older, men and non-pregnant women

• HIV RNA (viral load) of 2,000 copies or above

The study will last for about three years.

Exams and lab tests provided at no cost. Only TDF, EFV, LPV/r, and d4tXR will be provided by the study.

Subjects receive $20 per study visit.

Contact Alyssa or Lori at the ACTU at (206) 731-3184.